Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.
This study evaluates the safety and effectiveness of Atomoxetine for people with ADHD.
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Atomoxetine for people with ADHD.
Who could participate?
This study is for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00562055
- Official title
Show the full official title
Phase 2, Randomized, Double-Blind, Parallel-Group, Four Week, Efficacy And Safety Trial Of [S,S]-Reboxetine (PNU-165442g) And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.
Recruitment & locations
Locations not listed
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Atomoxetine for people with ADHD.
Who is behind this study?
The study sponsor is Pfizer.
Does this study involve medication?
Yes. The study involves medication, including Atomoxetine and PNU-165442G; [S,S]-reboxetine.
Who can participate?
This study is for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as withdrawn.
